567 related articles for article (PubMed ID: 28066861)
1. The incidence of cardiomyopathy in BRCA1 and BRCA2 mutation carriers after anthracycline-based adjuvant chemotherapy.
Pearson EJ; Nair A; Daoud Y; Blum JL
Breast Cancer Res Treat; 2017 Feb; 162(1):59-67. PubMed ID: 28066861
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.
Bignon L; Fricker JP; Nogues C; Mouret-Fourme E; Stoppa-Lyonnet D; Caron O; Lortholary A; Faivre L; Lasset C; Mari V; Gesta P; Gladieff L; Hamimi A; Petit T; Velten M
Breast J; 2018 May; 24(3):269-277. PubMed ID: 28929593
[TBL] [Abstract][Full Text] [Related]
3. The influence of BRCA1/BRCA2 mutations on toxicity related to chemotherapy and radiotherapy in early breast cancer patients.
Huszno J; Budryk M; Kołosza Z; Nowara E
Oncology; 2013; 85(5):278-82. PubMed ID: 24217135
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations.
Rennert G; Bisland-Naggan S; Barnett-Griness O; Bar-Joseph N; Zhang S; Rennert HS; Narod SA
N Engl J Med; 2007 Jul; 357(2):115-23. PubMed ID: 17625123
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study.
Goodwin PJ; Phillips KA; West DW; Ennis M; Hopper JL; John EM; O'Malley FP; Milne RL; Andrulis IL; Friedlander ML; Southey MC; Apicella C; Giles GG; Longacre TA
J Clin Oncol; 2012 Jan; 30(1):19-26. PubMed ID: 22147742
[TBL] [Abstract][Full Text] [Related]
6. Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclines.
Barac A; Lynce F; Smith KL; Mete M; Shara NM; Asch FM; Nardacci MP; Wray L; Herbolsheimer P; Nunes RA; Swain SM; Warren R; Peshkin BN; Isaacs C
Breast Cancer Res Treat; 2016 Jan; 155(2):285-93. PubMed ID: 26749359
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.
Kriege M; Seynaeve C; Meijers-Heijboer H; Collee JM; Menke-Pluymers MB; Bartels CC; Tilanus-Linthorst MM; Blom J; Huijskens E; Jager A; van den Ouweland A; van Geel B; Hooning MJ; Brekelmans CT; Klijn JG
J Clin Oncol; 2009 Aug; 27(23):3764-71. PubMed ID: 19564533
[TBL] [Abstract][Full Text] [Related]
8. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.
Kirova YM; Stoppa-Lyonnet D; Savignoni A; Sigal-Zafrani B; Fabre N; Fourquet A;
Eur J Cancer; 2005 Oct; 41(15):2304-11. PubMed ID: 16140006
[TBL] [Abstract][Full Text] [Related]
9. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
10. Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status.
Shah PD; Patil S; Dickler MN; Offit K; Hudis CA; Robson ME
Cancer; 2016 Apr; 122(8):1178-84. PubMed ID: 26859126
[TBL] [Abstract][Full Text] [Related]
11. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Jernström H; Lubinski J; Lynch HT; Ghadirian P; Neuhausen S; Isaacs C; Weber BL; Horsman D; Rosen B; Foulkes WD; Friedman E; Gershoni-Baruch R; Ainsworth P; Daly M; Garber J; Olsson H; Sun P; Narod SA
J Natl Cancer Inst; 2004 Jul; 96(14):1094-8. PubMed ID: 15265971
[TBL] [Abstract][Full Text] [Related]
12. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers.
Cullinane CA; Lubinski J; Neuhausen SL; Ghadirian P; Lynch HT; Isaacs C; Weber B; Moller P; Offit K; Kim-Sing C; Friedman E; Randall S; Pasini B; Ainsworth P; Gershoni-Baruch R; Foulkes WD; Klijn J; Tung N; Rennert G; Olopade O; Couch F; Wagner T; Olsson H; Sun P; Weitzel JN; Narod SA
Int J Cancer; 2005 Dec; 117(6):988-91. PubMed ID: 15986445
[TBL] [Abstract][Full Text] [Related]
13. Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom.
Shanley S; McReynolds K; Ardern-Jones A; Ahern R; Fernando I; Yarnold J; Evans G; Eccles D; Hodgson S; Ashley S; Ashcroft L; Tutt A; Bancroft E; Short S; Smith I; Gui G; ; Barr L; Baildam A; Howell A; Royle G; Pierce L; Easton D; Eeles R
Clin Cancer Res; 2006 Dec; 12(23):7033-8. PubMed ID: 17145825
[TBL] [Abstract][Full Text] [Related]
14. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
Lancet; 1997 May; 349(9064):1505-10. PubMed ID: 9167459
[TBL] [Abstract][Full Text] [Related]
15. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers.
Milne RL; Osorio A; Ramón y Cajal T; Baiget M; Lasa A; Diaz-Rubio E; de la Hoya M; Caldés T; Teulé A; Lázaro C; Blanco I; Balmaña J; Sánchez-Ollé G; Vega A; Blanco A; Chirivella I; Esteban Cardeñosa E; Durán M; Velasco E; Martínez de Dueñas E; Tejada MI; Miramar MD; Calvo MT; Guillén-Ponce C; Salazar R; San Román C; Urioste M; Benítez J
Breast Cancer Res Treat; 2010 Jan; 119(1):221-32. PubMed ID: 19370414
[TBL] [Abstract][Full Text] [Related]
16. Germline breast cancer susceptibility gene mutations and breast cancer outcomes.
Wang YA; Jian JW; Hung CF; Peng HP; Yang CF; Cheng HS; Yang AS
BMC Cancer; 2018 Mar; 18(1):315. PubMed ID: 29566657
[TBL] [Abstract][Full Text] [Related]
17. BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients.
Wunderle M; Gass P; Häberle L; Flesch VM; Rauh C; Bani MR; Hack CC; Schrauder MG; Jud SM; Emons J; Erber R; Ekici AB; Hoyer J; Vasileiou G; Kraus C; Reis A; Hartmann A; Lux MP; Beckmann MW; Fasching PA; Hein A
Breast Cancer Res Treat; 2018 Aug; 171(1):85-94. PubMed ID: 29725888
[TBL] [Abstract][Full Text] [Related]
18. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
[TBL] [Abstract][Full Text] [Related]
19. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
[TBL] [Abstract][Full Text] [Related]
20. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
